PTCT vs TPVG Stock Comparison: AI Score, Valuation, Performance and Upside
PTCT (PTC Therapeutics) and TPVG (TriplePoint Venture Growth) are unrelated businesses — PTC is a rare disease biopharmaceutical company with Skyclarys (Friedreich's ataxia), Emflaza (DMD), and international Translarna revenues, while TPVG is a BDC providing venture debt to VC-backed companies and paying high dividend income. PTC appeals to biotech investors seeking rare disease pipeline value; TPVG appeals to income investors seeking 8-12% dividend yields.
PTCT vs TPVG is rare disease biopharmaceutical with first-in-class Friedreich's ataxia treatment and RNA platform pipeline (PTC Therapeutics' Skyclarys commercial launch, Emflaza DMD revenue, and long-running Translarna international business — navigating FDA regulatory challenges and rare disease competition) versus high-yield venture debt BDC paying 8-12% dividends (TriplePoint Venture Growth's loan portfolio to VC-backed life sciences and tech companies — earning interest income and warrant upside while accepting venture default risk) — biopharmaceutical capital appreciation versus specialty finance income.
PTCT holds the edge across 3 of 5 key metrics in this comparison. PTCT has delivered stronger 1-year price return (+6.40% vs -6.17%), though TPVG has the better forward P/E setup (5.90x vs 28.72x for PTCT). On fundamentals, PTCT is growing revenue faster (101.50%), while TPVG maintains the higher operating margin (76.32%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for PTCT (+38.30%) than for TPVG (+20.52%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe Skyclarys (Friedreich's ataxia) launch success will establish PTC as a multi-product rare disease company with a substantially larger U.S. revenue base
- See PTC's RNA-targeting scientific platform as generating multiple future rare genetic disease pipeline opportunities
- Are willing to accept binary clinical milestones and Translarna FDA rejection risk in exchange for rare disease exposure at a potentially below-NAV valuation
- Seek high current dividend income (8-12% yield) from a specialty venture lender with life sciences and technology expertise
- Believe TriplePoint's top-tier VC firm relationships provide access to high-quality borrowers with lower-than-average default rates
- Want equity-upside participation in venture-backed company success through the warrant component alongside fixed income from loan interest payments
| Metric | PTCT | TPVG |
|---|---|---|
| AI scorei | 61.7 | 24.7 |
| AI ranki | #152 | #3127 |
| Latest closei | $66.90 | $4.84 |
| 1M returni | -9.18% | -6.54% |
| 6M returni | +2.46% | +9.16% |
| 1Y returni | +6.40% | -6.17% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PTCT | TPVG |
|---|---|---|
| 1Y ago | $10.64K (+6.4%) started 2025-09-18 | $11.44K (+14.4%) started 2025-09-18 |
| 5Y ago | $16.09K (+60.9%) started 2021-09-20 | $20.14K (+101.4%) started 2021-09-20 |
| 10Y ago | $60.88K (+508.8%) started 2016-09-19 | $238.27K (+2282.7%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | PTCT | TPVG |
|---|---|---|
| Market capi | $5.99B | $197.04M |
| Trailing P/Ei | N/A | 4.89 |
| Forward P/Ei | 28.72 | 5.90 |
| Price/Salesi | N/A | 2.20 |
| EV/Revenuei | 6.62 | 7.06 |
| Analyst targeti | $99.29 | $5.83 |
| Target upsidei | +38.30% | +20.52% |
| Metric | PTCT | TPVG |
|---|---|---|
| Revenue growthi | 101.50% | -5.20% |
| Earnings growthi | N/A | -19.80% |
| EPS growthi | N/A | -19.80% |
| FCF margini | -28.43% | +19.55% |
| Operating margini | 41.32% | 76.32% |
| Profit margini | -3.81% | 44.90% |
| ROIC proxyi | N/A | 11.45% |
| Return on equityi | N/A | 11.45% |
| Dividend yieldi | N/A | 15.15% |
| Payout ratioi | 0.00% | 94.95% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.55 | 1.38 |
| Debt/equityi | N/A | 125.89 |
| Current ratioi | 3.39 | 2.11 |
| Quick ratioi | 3.20 | 1.21 |
Over the past year, PTCT and TPVG have moved barely in the same direction (correlation of 0.02), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PTCT | TPVG |
|---|---|---|---|
| 1Y | Growthi | +6.40% | -6.17% |
| CAGRi | +6.41% | -6.17% | |
| Volatilityi | 39.85% | 34.74% | |
| Sharpe ratioi | 0.24 | -0.14 | |
| Sortino ratioi | 0.35 | -0.21 | |
| Max drawdowni | 27.17% | 29.97% | |
| Current drawdowni | 25.29% | 16.59% | |
| Avg drawdowni | 13.38% | 13.29% | |
| Ulcer Indexi | 15.67% | 15.38% | |
| Max daily dropi | 9.94% | 5.98% | |
| Max wkly dropi | 12.49% | 11.72% | |
| 5Y | Growthi | +60.87% | -32.43% |
| CAGRi | +9.99% | -7.55% | |
| Volatilityi | 55.05% | 32.48% | |
| Sharpe ratioi | 0.37 | -0.22 | |
| Sortino ratioi | 0.54 | -0.30 | |
| Max drawdowni | 69.42% | 54.79% | |
| Current drawdowni | 25.29% | 46.16% | |
| Avg drawdowni | 23.75% | 31.88% | |
| Ulcer Indexi | 29.30% | 34.41% | |
| Max daily dropi | 29.77% | 12.33% | |
| Max wkly dropi | 39.59% | 17.71% | |
| 10Y | Growthi | +508.78% | +68.05% |
| CAGRi | +19.81% | +5.33% | |
| Volatilityi | 65.10% | 67.96% | |
| Sharpe ratioi | 0.52 | 0.25 | |
| Sortino ratioi | 0.80 | 0.53 | |
| Max drawdowni | 73.78% | 81.78% | |
| Current drawdowni | 25.29% | 46.16% | |
| Avg drawdowni | 27.01% | 20.60% | |
| Ulcer Indexi | 32.21% | 26.77% | |
| Max daily dropi | 39.94% | 45.49% | |
| Max wkly dropi | 48.27% | 71.51% |
| Category | PTCT | TPVG |
|---|---|---|
| Company | PTC Therapeutics, Inc. | TriplePoint Venture Growth BDC Corp. |
| Sector | Healthcare | Financial Services - Business Development Company / Venture Debt |
| Industry | Biotechnology | Asset Management |
| Core business | PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Products include Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (DMD) — approved in the EU but not the U.S.; Emflaza (deflazacort) for Duchenne muscular dystrophy — approved in the U.S.; Skyclarys (omaveloxolone) — the first FDA-approved treatment for Friedreich's ataxia (approved February 2023); and pipeline candidates for alpha-1 antitrypsin deficiency and other rare conditions. PTC's scientific platform focuses on post-transcriptional regulatory mechanisms (splicing, nonsense mutation readthrough) that enable RNA-targeting therapeutic approaches. | TriplePoint Venture Growth BDC is a specialty finance company (Business Development Company) providing venture lending — secured loans, equipment financing, and revolving credit facilities — to growth-stage companies that have raised venture capital. TPVG's borrowers are VC-backed startups and growth companies in life sciences and technology seeking non-dilutive capital between equity funding rounds. TPVG earns interest income on its loan portfolio and charges origination fees; as a BDC, TPVG distributes substantially all income to shareholders as dividends, typically yielding 8-12% annually. |
| Investor focus | Investors track PTC's revenue from its commercial portfolio (particularly Skyclarys launch trajectory), clinical pipeline milestones, cash burn and runway, and prospects for U.S. Translarna approval (repeatedly rejected by FDA; approved in EU). | Investors track TPVG's net investment income (NII) per share, portfolio credit quality (default losses on venture loans), end-of-term payments and prepayments, and net asset value (NAV) per share. |
- Skyclarys (Friedreich's ataxia) is the first FDA-approved treatment for FA — positioning PTC as the commercial leader in a disease with no prior approved therapy; orphan drug pricing and 7-year exclusivity provide strong economic protection
- Multiple commercial products provide revenue foundation — Translarna (ex-U.S.) and Emflaza (U.S.) generate ongoing cash flow reducing binary pipeline dependency
- Friedreich's ataxia patient community is highly motivated and organized, supporting reimbursement advocacy — the FA patient community has been waiting decades for an approved therapy; strong patient advocacy supports payer coverage decisions
- Venture debt provides high current income with equity upside through warrants — loan interest rates of 10-14% plus warrants in borrowers; if borrowers succeed and go public or are acquired, warrant value adds to returns
- BDC pass-through structure provides tax transparency and high dividend yield — TPVG distributes nearly all income as dividends; historically 8-12% yield attractive for income-focused investors
- Life sciences and technology expertise aligns TPVG with high-quality VC dealflow — TriplePoint Capital's deep VC relationships provide access to top-tier venture-backed borrowers with lower-than-average default rates
- Translarna has faced repeated FDA rejection for U.S. approval — U.S. approval would dramatically expand the addressable market but regulatory pathway has been elusive after multiple attempts
- Rare disease competition is intensifying as large biotechs and gene therapy companies target DMD — Sarepta Therapeutics has exon-skipping therapies and gene therapy for DMD; commercial competition limits Emflaza's market position
- Cash burn from pipeline development and Skyclarys commercial launch requires financing discipline — PTC is not yet fully self-funding; continued investment in launch activities requires careful cash management
- Venture-backed company defaults are the primary credit risk — if borrowers fail (startup fails, VC backing stops), TPVG may recover less than loan value from secured collateral; default rates depend on the macro environment and VC funding availability
- Interest rate environment affects BDC returns and valuations — rising rates increase TPVG's borrowing costs; falling rates reduce income on floating-rate loans and depress dividends
- External management structure creates potential conflicts of interest — TriplePoint Capital manages TPVG and earns management fees; the structure may not always align manager incentives with TPVG shareholder interests
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.